Breath Diagnostics
About
Breath Diagnostics is developing technology to detect diseases with a single breath. Raised $326,905 in the week ending Feb 21, 2026. Non-invasive breath analysis could revolutionize early disease detection across cancer, infections, and metabolic conditions.
AI Investment Summary
Breath Diagnostics aims to detect disease through breath analysis — a potential game-changer for non-invasive diagnostics. Active campaign raising $326K+ per week on Wefunder.
Structure
Direct Equity
Stage
Seed
Accreditation
Open to All
Liquidity
Illiquid
Geography
United States
Revenue
pre revenue
Total Investors
450
Green Flags
- Non-invasive disease detection
- Strong fundraising momentum ($326K/week)
- Large addressable market in diagnostics
- Could reduce costly invasive tests
Risk Flags
- Pre-revenue medical device startup
- FDA regulatory pathway uncertain
- Breath diagnostics is early-stage science
- Capital-intensive R&D
Similar Deals in Healthcare
DNA Chat (Mendly Care)
Seed
AI telemedicine + genome sequencing platform — $400 per genome.
Min. Investment
$100
Funded
25%
NeuralMed
Series A
FDA-cleared AI cancer detection — 97% accuracy, deployed at 45 hospitals.
Min. Investment
$250
Funded
64%
Vybe Medical
Series A
AI-assisted mental health platform — $65/session, 25K patients.
Min. Investment
$200
Funded
58%
Minimum Investment
$100
Lock-up Period
5 years (until exit)
Tags
LISTED
2026-02-01